David Liu, Ph.D., joined Vivo with over 15 years of experience in process R&D and CMC management in the pharmaceutical industry. He has led the development and implementation of novel and efficient chemical processes for tens of programs ranging from pre-IND to late stage Phase III.

Prior to Vivo, he worked at STA-WuXi Apptec as Executive Director of Process Research & Development. Prior to STA, he was Director of Process Chemistry with Avista Pharma Solutions and Principal Research Investigator with Array BioPharma.

David received his B.S. and M.S. in Chemistry from Peking University and Ph.D. in Organic Chemistry from University of Pittsburgh. He completed his postdoctoral research at Texas A & M University.

Ms. Wang joined Bain Capital in 2014. She currently is a Managing Director of Bain Capital Life Sciences Team. She is responsible for healthcare investment in the Great China, and participated in transactions including Asia Pacific Medical Group, Avistone, Tenacia, Seran Biosciences, etc.

Prior to joining Bain Capital, Ms. Wang worked at Hony Capital as an investment analyst, and involved in transactions including Simcere Pharmaceutical, Biosensors International, and Yangsi Hospital.

Ms. Wang holds a Master's Degree of Finance from Peking University and a BA in Economics from Fudan University.

Jiaqi Zheng is a founding member and partner of Primavera Capital Group. He leads or co-leads the firm's investments in healthcare and TMT sectors. Jiaqi led or played an important role in a broad range of investment deals including ByteDance, LBX Pharmacy Chain, Jenscare Biotechnology, Avistone Pharmaceuticals, OptoMedic, Shukun Technology, Asia Medical, Symap Medical, OASIS International Hospital, Ubox Technology, as well as the cross-border joint acquisition of Iovate Health Sciences and the privatization of Shanda Games, Focus Media and Chemspec. He currently serves on the boards of LBX Pharmacy Chain, Jenscare Biotechnology, Avistone Pharmaceuticals, Asia Medical and Iovate Health Sciences.

Prior to Primavera Capital Group, he previously worked at the Investment Banking Department of China International Capital Corporation.

Jiaqi Zheng holds a Bachelor of Arts in Economics from the University of Manchester and a Master of Science in Finance from Lancaster University.

Mr. Du is an Investment Director of CS Capital. He is responsible for medical and health field investment. Mr. Du participated in or led investment projects including Cstone Pharmaceutical (2616.HK), Ascentage Pharma, Biocytogen, Crystal Pharmatech, JW Therapeutics (2126.HK), Tyligand Bioscience, Avistone Biotechnology, etc.

He previously worked at Suzhou Oriza Holdings Corporation as an Investment Analyst, an Investment Manager and a Vice President.

Mr. Du holds an MBA degree from Shanghai Advanced Institute of Finance of Shanghai Jiao Tong University, a Master's degree in biotechnology from the University of Queensland, Australia, and a Bachelor's degree in biotechnology from Zhejiang Sci-Tech University.

As a founding member of Avistone, he is responsible for the development of innovative drugs. He has over 17 years of experience in innovative drug development, having led multiple new drug projects. He is the primary inventor of several clinical-stage drug candidates and directed numerous clinical studies. His expertise in small-molecule targeted drug design has led to significant breakthroughs, and he is recognized as an innovative team leader with extensive management experience.

As one of the founding team members, he is responsible for promoting the company's pre-listing tutoring and subsequent IPO work, as well as the post-listing company's information disclosure, investor relations, corporate governance, equity investment, the preparation for the board of directors and shareholders' meetings etc.

As a founding member of Avistone, he is responsible for the clinical development of the company's innovative drugs. He has over 10 years of experience in innovative drug development and leads several clinical research projects including Vebreltinib’s project. He has undertaken the Ministry of Science and Technology's "13th Five-Year Plan Major New Drug Creation and Development Program" and Beijing Municipal Government's "Clinical Research of Innovative Therapeutic Candidates and Key Technology Upgrades" special project. He has expertise in clinical protocol design and project management.

She is responsible for the establishment and implementation of the company's talent and organizational development strategies, including recruitment, training and growth, compensation and benefits, performance management and employee relations. With over 10 years of work experience in the pharmaceutical industry and human resources positions, she has accumulated rich experience in strategic planning, talent recruitment, development, and retention.